Skip to main content
. 2017 Dec 22;2017(12):CD011535. doi: 10.1002/14651858.CD011535.pub2

Figure 16.

Figure 16

Serious adverse effects: direct summary effects for comparisons including at least two studies at class level

AIL12/23: anti‐IL12/23; AIL17: anti‐IL17; AIL23: anti‐IL23, ATA: anti‐TNF alpha; CSA: conventional systemic agents; OB: other biologics; PBO: placebo; SM: small molecules

CI: confidence interval; RR: risk ratio; SAE: serious adverse events